Cambridge Biolabs offers consulting and wet laboratory services to support RNAi companies.
Dr. Fruehauf is a well-recognized expert in RNAi therapeutics, and offers consulting services to RNAi companies at all stages. His expertise covers the delivery of RNAi triggers and novel trigger structures as well as regulatory pathway for RNAi drug candidates. He is an active member of the Oligonucleotides Safety Working Group (OSWG), for the development of guidelines for nucleic acid therapeutics. His past or present clients include Cequent Pharmaceuticals, Marina Biotech, Aura Biosciences, BioMolecular Therapeutics, and others. Publications.
CBL’s team has been successful in completing numerous RNAi related projects for our clients, ranging from miRNA therapeutics to biologic delivery of nucleic acids. This success is documented in the filing of three RNAi-related patent applications and two successful RNAi-related grant applications for our clients within the past 12 months.